Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy-Reference-Cited by-同舟云学术

Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy

Published:2014-11-27 Issue:2 Volume:17 Page:202-206
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Hollander P.¹,King A. B.²,Del Prato S.³,Sreenan S.⁴,Balci M. K.⁵,Muñoz‐Torres M.⁶,Rosenstock J.⁷,Hansen C. T.⁸,Niemeyer M.⁹,Garber A. J.¹⁰

Affiliation:

1. Baylor University Medical Center Dallas TX USA

2. Diabetes Care Center Salinas CA USA

3. Section of Diabetes, University of Pisa Pisa Italy

4. Department of Endocrinology, Connolly Hospital Dublin Ireland

5. Department of Internal Medicine, Division of Endocrinology and Metabolism, Akdeniz University Faculty of Medicine Antalya Turkey

6. Hospital Universitario San Cecilio Granada Spain

7. Dallas Diabetes and Endocrine Center Dallas TX USA

8. Novo Nordisk Søborg Denmark

9. Novo Nordisk Frankfurt Germany

10. Department of Medicine—Division of Endocrinology, Baylor College of Medicine Houston TX USA

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12411

Reference6 articles.

1. Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

2. Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

3. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

4. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

5. Lower within‐subject variability in mean blood glucose concentration with insulin degludec vs. insulin glargine: a meta‐analysis of patients with T2D;Meneghini LF;Diabetes,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin for people with type 2 diabetes mellitus;BMJ;2024-07-17

2. Insulin Degludec in People with Type 2 Diabetes in China: A Non-interventional, Retrospective Chart Review Study (CN-TREAT);Diabetes Therapy;2024-03

3. Functional insulin aspart/insulin degludec-based microneedles for promoting postprandial glycemic control;Acta Biomaterialia;2023-11

4. Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis;Clinical Therapeutics;2022-11

5. Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus;Diabetes Therapy;2022-06-30